Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections

Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections

US Patent 11028151 · Granted Jun 8, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD8 binding agents2025
Modulation of dendritic cell lineages2025
CLEC9A-based chimeric protein complexes2025
PD-1 and PD-L1 binding agents2025
Polypeptides antagonizing Wnt signaling in tumor cells2025
Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin sin2025
Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)2024
Methods and compositions for the preparation of aerosols2024
Antigen-binding polypeptides directed against CD382024
Techniques for predicting, detecting and reducing aspecific protein interference2024
Biparatopic polypeptides antagonizing Wnt signaling in tumor cells2024
Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin2024